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Dexamethasone for 
COVID-19: data needed 
from randomised 
clinical trials in Africa
Over the past 6 months, potential 
COVID-19 treatments have come 
under intense scrutiny on social media, 
shifting the public discourse without a 
strong scientific rationale. There are 
now preliminary data showing that, 
in patients from Europe, low-dose 
dexamethasone reduces mortality 
by up to 33% in the most severely 
affected patients needing invasive 
ventilation (rate ratio 0·65, 95% CI 
[0·51–0·82]; p<0·001) and by 20% in 
those needing oxygen (rate ratio 0·80, 
95% CI [0·70–0·92]; p=0·002).1 We 
welcome the RECOVERY trial1 results 
and support the implementation of 
dexamethasone as standard of care 
in settings similar to the trial sites. 
However, there is a need for caution 
regarding the results of a single, albeit 
well designed, trial done in a high-
income country to change guidelines 
elsewhere in the world where the 
population and the context of care 
might be vastly different.
Despite a slow start in Africa, the 
incidence of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) 
infections is rapidly evolving, with 
more than 468 000 confirmed cases 
and 11 144 known deaths as of 
July 5, 2020.2 As SARS-CoV-2 spreads 
through Africa, already weakened 
health systems and the few critical-care 
facilities will come under increasing 
strain, with potential for higher 
COVID-19-associated mortality and 
more collateral damage than observed 
in high-income countries. The African 
pandemic has not yet reached its peak 
in most countries, many of which are 
easing social restrictions to minimise 
the effect on livelihoods. Hence, 
COVID-19 prevalence and mortality 
are likely to accelerate further over 
the coming months. Dexamethasone 
has substantial potential to prevent 
death as this treatment could be 
easily deployed in an African setting. 
Nevertheless, the medical and 
scientific community should be wary 
of assuming that evidence for steroids 
generated in Europe also applies to 
African populations and robust African 
data are urgently needed.
In a search for COVID-19 treatments 
we should be guided by context-
specific evidence, learning from 
previous controversies on the use of 
steroids in Africa. Antenatal cortico-
steroids, a cornerstone of modern 
obstetric care to reduce mortality in 
premature neonates, are an example.3 
Antenatal corticosteroids were 
recommended as standard of care for 
threatened preterm labour based on 
evidence mostly from high-income 
countries. Four decades after the 
first randomised controlled trial, a 
large cluster-randomised controlled 
multicentre trial in low-income and 
middle-income countries showed no 
benefit of antenatal corticosteroids 
for the smallest neonates, increased 
mortality for all neonates, and 
increased risk of maternal infection.4 
The increased mortality outcomes were 
mostly observed in African sites, with 
speculation that increased infections 
and undetected hypoglycaemia 
contributed to worse outcomes.4 The 
results generated much controversy 
and resulted in more targeted 
promotion of antenatal corticosteroids 
by WHO. However, as the evidence 
emerged long after the acceptance 
of this treatment as standard of 
care, delineating and implementing 
appropriate use in low-income and 
middle-income countries has been 
challenging. Similarly, the use of 
steroids as adjuvant treatment for 
presumed bacterial meningitis is 
supported by evidence from high-
income countries, and recommended 
by guidelines in these settings.5 
However, steroids have shown no 
benefit when studied in well designed 
trials in low-income and middle-
income countries.6 Corticosteroids 
might also precipitate sepsis in some 
parasitic infections prevalent in Africa 
(eg, strongyloides),7 and are associated 
with progression of latent to active 
tuberculosis and development of 
opportunistic infections in immuno-
suppressed patients,8 all of which might 
be undiagnosed in patients from Africa 
with COVID-19 and could result in 
unintended consequences.
There are still many unknowns 
about the epidemiology and severity 
of risk factors for COVID-19 in Africa. 
The effect of infectious disease 
comorbidities, such as malaria, parasitic 
infections, HIV, and tuberculosis, as 
well as genetic factors, nutritional 
status, and vaccination history on the 
inflammatory response to COVID-19 is 
not yet fully understood. Such effects 
might be important for the response 
to, and safety of, treatments, including 
steroids. The risk of secondary 
bacterial infection has not yet been 
quantified and cannot be assumed to 
be equivalent to high-income country 
settings, as prevalence of nosocomial 
bacterial infections is greater in low-
income and middle-income countries.9 
Limitations within health systems 
in any setting might influence the 
effectiveness of the intervention 
and change the risk–benefit balance. 
For example, a reduced capacity to 
monitor blood sugar concentrations or 
detect comorbidities in which steroids 
are contraindicated might result in 
adverse outcomes. Conversely, steroids 
could have an even greater mortality 
effect in the absence of critical-care 
facilities and adequately trained 
staff than in high-income settings, 
which could transform COVID-19 
management in Africa.
As much as we welcome dexa-
methasone as a treatment for severe 
COVID-19 pneumonia in high-
income countries, the scientific 
and medical community  must 
adhere to the principle of “first, do 
no harm”. Therefore, we advocate 
for timely generation of region-
specific data for and against steroid 
efficacy from well designed African 
randomised controlled trials before 
recommending the incorporation 
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of dexamethasone into treatment 
guidelines for COVID-19-associated 
severe pneumonia in Africa.
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